Enoxaparin 40 Mg/0.4 mL Injectable Solution

DRUG3 trials

Sponsors

IRCCS Azienda Ospedaliero-Universitaria di Bologna, General Committee of Teaching Hospitals and Institutes, Egypt, Egyptian International Pharmaceutical Industries Co

Conditions

Anastomotic LeakageBlood LossBlood TransfusionCOVID-19Healthy Participants StudyIntensive CareLymph Node DiseaseSurvival

Phase 1

Study to Determine the Comparative Pharmacodynamics of Enoxaparin Sodium Biosimilar With That From Clexane

Not yet recruitingNCT07517289

Egyptian International Pharmaceutical Industries CoHealthy Participants Study, The Focus of the Study is to Determine the Comparative Pharmacodynamic of Enoxaparin Sodium With That of Clexane in Healthy Human Participants

Start: 2026-04-30End: 2026-08-01Target: 26Updated: 2026-04-08

Phase 2

Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients

CompletedNCT04427098

IRCCS Azienda Ospedaliero-Universitaria di BolognaCOVID-19

Start: 2020-05-22End: 2021-09-29Updated: 2024-12-03

Unknown Phase

D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy

Not yet recruitingNCT06049758

General Committee of Teaching Hospitals and Institutes, EgyptAnastomotic Leakage, Blood Loss, Blood Transfusion +3

Start: 2024-01-02End: 2030-01-02Target: 80Updated: 2023-09-22

Related Papers

Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19.

2023-10-242 citations